Loading...

NSS

NSRX

NASUS PHARMA LTD

(NSRX)

2026 6-K

Business Update

25 Mar '26

Positive Clinical Data

16 Mar '26

Shareholder Meeting Results

6 Mar '26

Virtual Shareholder Meeting

4 Mar '26

Funding Announcement

13 Feb '26

Private Placement

11 Feb '26

Shareholder Meeting Notice

29 Jan '26

Positive Interim Results

20 Jan '26

Financial Report

29 Dec '25

CEO Shareholder Letter

22 Dec '25

Leadership Appointment

20 Nov '25

Clinical Trial Launch

18 Nov '25

Corporate Presentation Release

3 Nov '25

Collaboration Update

8 Oct '25

IPO Update

30 Sep '25

Board Changes

5 Sep '25

External Links:

SEC

On March 16, 2026, Nasus Pharma Ltd. announced favorable results from a Phase 2 study of NS002, showing faster epinephrine delivery compared to EpiPen®. This event is significant for the company and holds a positive sentiment for investors.

AI Assistant

NASUS PHARMA LTD

2026

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.